Introduction
The role of Vascular Endothelial Growth Factor (VEGF) in solid tumor pathologies has been extensively investigated and evidence has recently emerged that it may also have a role in hematological malignancies.
1,2 VEGF expression by neoplastic cells has been demonstrated in non-Hodgkin lymphomas and has been correlated with tumor progression and poor survival rates. 3 VEGF promotes the formation of new blood vessels by stimulating endothelial cell division and migration; this neo-vascular network allows tumor growth and metastasis. 4 Regulation of VEGF occurs at multiple levels, including transcription, mRNA stabilization and splicing, and translation. 5, 6 MicroRNAs (miRNAs) are 20-25-nucleotide-long non-coding RNAs that act as negative regulators of gene expression. They bind to a specific sequence of mRNA, usually located in the 3 0 -UTR (untranslated region). This interaction can lead either to targeted mRNA cleavage or to repression of mRNA translation, in both cases resulting in reduced levels of the encoded protein. 7 miRNAs are important in the regulation of cellular differentiation, proliferation and apoptosis. 8 Some miRNAs are considered to be oncogenes or tumor suppressors and are aberrantly expressed in tumors including hematological malignancies. 9, 10 Aberrant expression of miRNAs can arise via a number of different mechanisms, such as genomic abnormalities or epigenetic modifications. [9] [10] [11] Recently, several miRNAs have been found to regulate angiogenic processes. 12 Notably, miR-15a and miR-16-1 have an important role via regulation of VEGF expression. 13 miR-16, is downregulated by hypoxia, 14 supporting the notion that a hypoxia-induced reduction of miR-16 levels contributes to an increase in VEGF expression. Anaplastic lymphoma kinase (ALK) fusion proteins (onco-ALK) have been detected in several human malignancies, including Anaplastic Large Cell Lymphomas (ALCL), 15 diffuse large B-cell lymphomas 16, 17 and a wide variety of solid cancers, such as inflammatory myofibroblastic tumors 18 and non-small cell lung cancers. 19 The mechanisms of malignant cell transformation mediated by oncogenic ALK tyrosine kinase expression are not clearly understood. Recently, Marzec et al. reported that ALK-positive (ALK þ ) ALCL strongly express hypoxia-induced factor 1a (HIF1a) mRNA, even under normoxic conditions. They found that inhibition of HIF1a expression markedly suppressed cell growth and proliferation and decreased VEGF synthesis in ALCL cell line. 20 As lymphoma tissues are predominantly under hypoxic conditions, it is possible that HIF1a has an important role in the pathogenesis of ALK þ ALCL.
Compared with ALK-negative (ALKÀ) ALCL, ALK þ ALCL have a better prognosis when undergoing CHOP-based chemotherapy, 21, 22 however, ALK þ ALCL relapses after chemotherapy are very invasive and have a worse prognosis. 23 , 24 We recently developed conditional mouse models for NPM-and TPM3-ALKinduced lymphomagenesis using the tetracycline system. 25 In these models, ALK oncogenes induce B lymphoma formation associated with a robust angiogenesis. Although these models do not truly reproduce the human disease, they represent a powerful tool to investigate the molecular mechanisms involved in ALKassociated disorders.
Until now, the role of VEGF in ALCL development and posttreatment relapse has not been studied. Here, we used onco-ALK (NPM-ALK and TPM3-ALK) mouse conditional MEF cell line (ALK þ fibroblasts), 25 as well as transgenic models (ALK þ B-lymphoma), 26 to both determine whether ALK oncogenes regulate VEGF levels and tumor angiogenesis and investigate the mechanisms involved.
Materials and methods

Conditional murine models
Generation of conditional transgenic mice and MEF Tet-OFF cells (Clontech, Saint Quentin Yvelines, France) for expression of NPM-ALK or TPM3-ALK oncogenes was described by Giuriato et al. 25, 26 The tetracycline regulatory system was used to control the transgene transcription. The addition of doxycycline (an analog of tetracycline) allowed silencing of onco-ALK expression (OFF condition, ALK-), whereas doxycycline removal permitted onco-ALK expression (ON condition, ALK þ ). Lymph nodes from ALK þ , ALKÀ and healthy mice, that is, normal littermate transgenic mice were used for RNA and DNA extractions.
Tumor and normal samples
The study was carried out in accordance with the institutional review board-approved protocols and the procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000. The diagnosis of ALCL was based on morphologic and immunophenotypic criteria as described in the last WHO classification. 27, 28 The percentage of malignant cells was assessed by ALK1 or CD30 staining and was greater than 80% for all selected cases. Frozen tumor samples from 20 ALK þ ALCL, 6 ALKÀ ALCL, and 5 reactive lymph nodes were retrieved from the tumor bank from Toulouse CHU and used for RNA and DNA extractions. A total of 100cases with available paraffin blocks, of which 86 cases were positive for the ALK protein, were used to prepare tissue microarrays. Sera from ALCL patients (ALK þ : n ¼ 17 and ALKÀ: n ¼ 16) and five healthy donors were used to perform VEGF ELISA.
RNA preparation
Total RNA was prepared using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The concentration of RNA was quantified using a NanoDrop Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). RNA integrity was evaluated using an Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA). RNAs with an RNA integrity number 47.5 were used for miRNA and mRNA quantifications.
Real-time RT-PCR assays
All qPCR were performed using an ABI 7300 Real-Time instrument (Applied Biosystems, Foster, CA, USA). TaqMan miRNA assays (Applied Biosystems, CA, USA) were used to measure miR-15a and miR-16 expression following manufacturer's instructions. RNU24 for human and SnoRNA202 for mice served as internal controls.
Expression of S14, HIF1a and VEGF genes were estimated by qPCR using a primer pair designed as follows: for human or mouse VEGF, the forward primer was 5 0 -CGAGATAGAGTA CATCTTCAAGC-3 0 and the reverse primer was 5 0 -TTGATCCG for human and the forward primer was 5 0 -GGTGGCTGAGG GAGAGAATG-3 0 and the reverse primer was 5 0 -CTCGGCA GATGGGTTTCCTTG-3 0 for mouse. cDNA was synthesized from total RNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA). qPCR was performed using SYBR green real-time PCR master mix (Eurogentec, Angers, France). The PCR mixture (25 ml) consisted of 12.5 ml master mixture, 0.75 ml for each PCR primer at 10 mM, 5 ml diluted cDNA and 6 ml DNase and RNase free water. qPCR was done using 40 cycles of 15 s at 90 1C and 1 min at 60 1C.
Relative fold changes of miRNA and target transcript expression were calculated by the DDCT method and the values were expressed as 2(ÀDDCT). Detected target transcripts were normalized to the endogenous housekeeping gene S14.
miRNA northern blotting
Northern blots were performed using 10 mg of total RNA on denaturing PAGE. After blotting on Amersham Hybond-N þ , miR oligonucleotides complementary to miR-15a and miR- 16 5 0 -end-labeled using T4 polynucleotide kinase and g-32 P ATP, were used as a probe.
miRNA transient transfections and target validations
MEF-TPM3-ALK cells 25 were transfected with 50 nM of pre-miR15a (miR-15a) or pre-miR-16 (miR-16) (Ambion, Applied Biosystems, Austin, TX, USA), negative control miRNA (premiR control no. 1 or scramble; Ambion, Applied Biosystems), locked nucleic acid (LNA) (5 0 -CGCCAATATTTACGTGCTGCTA-3 0 ) (LNA-16) (Sigma-Aldrich Chimie, Saint-Quentin Fallavier, France) or anti-miR-16 (Ambion, Applied Biosystems), using MEF transfection reagent (Altogen, Las Vegas, NV, USA) following the manufacturer's protocol. The expression of miR-16 was detected by RT-qPCR 48 h after transfection.
MEF-TPM3-ALK cells were transfected with 20 ng of pRLCMV-VEGF 3 0 -UTR wild-type (pRL-VEGF 3 0 -UTR) 29 and 250 ng of pCMV-b-Gal control vector serving as transfection control in a 12-well plate. For the co-transfection of miR-16, LNA-16, anti-miR-16 or scrambled miRNA was added with the reporter vectors, 50 nM of each miRNA or 50 nM of each inhibitor or control was transfected using Lipofectamine 2000 (Invitrogen, Cergy Pontoise, France). Cell lysate was collected and assayed 48 h after transfection. Renilla luciferase (LucR) activities were measured with a luminometer (Centro LB960, Berthold, Berthold Technologies, Thoiry, France) using the Luciferase Reporter Assay (Promega) and galactosidase activity was measured using the b-galactosidase enzyme assay system (Promega) according to the manufacturer's instructions. The results are expressed as relative luciferase activity/galactosidase activity.
All transfections and measurements were performed in triplicate and repeated at least three times.
VEGF ELISA
In all 96-well plates coated with anti-mouse or -human VEGF monoclonal antibody (Calbiochem, Merck KGaA, Darmstadt, Germany) were used to measure VEGF secretion following the manufacturer's guidelines. Absorbance was measured at 450 nm miR-16 and VEGF expression in ALK lymphomas E Dejean et al with a wavelength correction at 570 nm. Each experiment was performed in triplicate and repeated three times.
VEGF and HIF1a immunohistochemistry
Sections (5 mM) were cut from each tissue microarray, deparaffinized, subjected to heat antigen retrieval and stained with rabbit polyclonal anti-VEGF antibody (A20, 1/40 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-HIF-1a antibody (clone H1a67, 1/100, Novus Biologicals, Cambridge, UK). Antibody binding was detected with Dako REAL Detection System (Code K5001, Dako France, Trappes, France). The percentage of positive cells was evaluated using a Leica DMR microscope (Leica Geosystems France, Le Pecq, France) equiped with a DFC300FX camera and a Â 200/0.85 NA objective lens. Cases were considered positive when more than 10% of neoplastic cells were stained. Image processing was performed using the IM50 software from Leica Geosystems France.
DNA methylation analysis
We searched the human and mouse genome database (http:// genome.ucsc.edu/) (University of California Santa Cruz, Genome Bioinformatics) for the existence of miRNAs embedded in a CpG island. Genomic DNA samples were modified by sodium bisulfite using the CpGenome DNA modification kit (Chemicon, Temecula, CA, USA) following the manufacturer's instructions. The DNA methylation status was analyzed by methylation-specific PCR after sodium bisulfite modification of DNA. Human male and mouse genomic DNA universally methylated for all genes (Intergen Company, Purchase, NY, USA) was used as a positive control for methylated alleles. Water blanks were included with each assay. The deleted in leukemia and structural maintenance of chromosomes-4 genes are the host genes for miR-16-1 and miR-16-2, respectively. Primer sequences of methylation-specific PCR of miR-16 are described in Supplementary Table S2 . Following amplification, PCR products were subjected to gel electrophoresis through a 2.5% agarose gel and were visualized by ethidium bromide staining and UV transillumination.
Tumorigenicity assays
MEF-TPM3-ALK cells 25 were transfected, as described above, with pre-miR-16 or scrambled control miRNA (pre-miR control no. 1), resuspended in PBS (2 Â 10 6 cells/site) and then injected subcutaneouslyinto female Balb/c nu/nu mice, 4-6 weeks old (Iffa Credo, L'Arbresle, France). Five mice were used for each tested condition. Tumor volume was calculated as v ¼ length (mm) Â width (mm) Â thickness (mm) Â 0.52 and measured every 2 days.
Statistical analysis
Values were expressed as mean ± s.d. Non-parametrical MannWhitney test and/or unpaired t-test or two-way ANOVA were applied to analyze the differences between groups. Analyses were performed using GraphPad Prism version 4.00 for Windows (San Diego, CA, USA). Po0.05 was considered to be significant.
Results
VEGF overexpression and miR-16 downregulation in murine onco-ALK models
We have previously developed conditional transgenic mice that express onco-ALK (NPM-ALK and TPM3-ALK) and exhibit robust angiogenesis (Supplementary Figure S1a) . These mice were used to investigate whether ALK oncogene expression induces an increase in VEGF mRNA levels using RT-qPCR. We observed that the level of VEGF mRNA was significantly upregulated in lymph nodes isolated from mice with ALK þ tumors (Supplementary Figure S1b ) when compared with lymph nodes isolated from normal littermate transgenic mice (normalized to 1) and from onco-ALK OFF healthy mice (Supplementary Figure S1b) . We next checked whether the ALK oncogene-mediated increase in VEGF mRNA was followed by an increase in VEGF protein levels. The amount of secreted VEGF was measured by performing ELISA assays on mice sera. We observed that VEGF secretion was significantly upregulated in sera prepared from mice with ALK þ tumors in comparison with sera prepared from onco-ALK OFF healthy mice (P: 0.0173 for NPM-ALK; P: 0.0303 for TPM-ALK) and from control littermate animals (Supplementary Figure S1c ).
Since miR-15 and miR-16 contribute to an increase in VEGF, 14 we used northern-blotting to compare miR-15a and miR-16 expression levels in tumor lymph nodes isolated from onco-ALK transgenic mice (ALK þ ) with lymph nodes isolated from doxycycline-treated animals (ALKÀ) (Supplementary Data). To test for significant differences in expression of miR-15 and miR-16, two statistical tests (the two-sample t-test and the Mann-Whitney test) were performed (Supplementary Table S1 ). In onco-ALK mice (ALK þ ), we found that miR-15a and miR-16 were significantly downregulated in lymphoma cells when compared with lymph node cells isolated from onco-ALK OFF healthy mice (ALKÀ) (0.471±0.086 vs 0.761±0.058 mean expression for miR-15a; 0.493 ± 0.025 vs 0.863 ± 0.044 mean expression for miR-16) (Supplementary Table S1 ).
To further confirm the upregulation of VEGF levels and the downregulation of miR-15a and miR-16 in onco-ALK-expressing cells in vitro, we used another murine onco-ALK model: MEF cells conditionally expressing the TPM3-ALK oncogene (MEF-TPM3-ALK cells). 25 Using ELISA assays, we observed a substantial increase in secreted VEGF (mean: 617±126.33 pg/ml; p: 0.0318) in the supernatants of MEF TPM3-ALK-positive cells (ALK þ ) when compared with MEF TPM3-ALK-negative cells (ALKÀ) (Figure 1a ). These data are consistent with the results obtained in transgenic mice harboring onco-ALK lymphomas (Supplementary Figures S1b and c and Supplementary Table S1 ). No significant variation in VEGF mRNA levels was observed between ALK þ and ALKÀ conditions (Figure 1b) . We therefore used RT-qPCR, to analyse the expression levels of miRNA and observed that ALK þ cells express reduced levels of miR-15a and miR-16 when compared with ALKÀ cells (Figure 1c) , however only miR-16 downregulation was significant (Po0.05) (Figure 1c) . Altogether, these results suggest that miR-16 downregulation contributes to a decrease in VEGF levels in ALK þ cells.
VEGF mRNA is an miR-16 target in MEF TPM3-ALK cells
To understand the role of miR-16 in controlling VEGF levels, we looked at the consequences of either over-expressing or silencing miR-16 in ALK þ cells. The amount of miR-16 in transfected ALK þ cells was more than 700 fold higher than in control cells (Supplementary Figure S2) . Transfection with miR-16, but not with the negative controls, resulted in a significant decrease in secreted VEGF protein levels 48 h after transfection (Figure 2a) . Conversely, when endogeneous miR-16 was downregulated using an antisense locked nucleic acid to miR-16 (LNA-16), we observed an increase in VEGF secretion miR-16 and VEGF expression in ALK lymphomas E Dejean et al ( Figure 2a ). Importantly, RT-qPCR did not show any differences in VEGF mRNA levels under all transfection conditions (Figure 2b ). Thus, miR-16 levels inversely correlate with VEGF protein levels with mRNA levels unaffected. We therefore postulated that, in ALK þ cells, VEGF is controlled by miR-16 at a translational level.
To investigate further, we used a LucR reporter construct to examine whether miR-16 regulated VEGF translation through binding to its target site in the VEGF mRNA 3 0 -UTR. LucR activity was 6.5-fold lower in ALK þ cells transfected with miR-16 when compared with a scrambled miRNA control normalized to 1 (Po0.001, two-way ANOVA) (Figure 2c ). Transfection with LNA-16 (Po0.05, two-way ANOVA) or a chemically modified inhibitor against miR-16 (anti-miR-16) (Po0.01, two-way ANOVA) led to a significant increase in the normalized LucR activity in ALK þ cells when compared with miR-16 transfection (Figure 2c) . In ALK-inactivated cells (ALKÀ), reporter activity was not significantly changed under all conditions (Figure 2c) . We conclude that, in ALK þ cells, VEGF mRNA is a target for miR-16 binding and that VEGF expression is controlled, at least in part, by the amount of miR-16.
miR-16 downregulation is not dependent on DNA loss and epigenetic modifications in murine TPM3-ALK models
In an attempt to identify the mechanisms involved in miR-16 downregulation in murine onco-ALK models, we first searched for DNA loss by high-resolution array-based comparative genomic hybridization array analysis (see Supplementary Data), on tumoral lymph nodes from TPM3-ALK transgenic mice. DNA karyotype changes did not seem to be involved in miR-16 downregulation (data not shown).
Mus musculus miR-16 is expressed from two loci, deleted in leukemia 2 located on chromosome 3 and structural maintenance of chromosomes-4 located on chromosome 14; these code for miR-16-1 and miR-16-2, respectively. We sought to determine whether aberrant methylation of the putative promoter regions of deleted in leukemia 2 and structural maintenance of chromosomes-4 was responsible for miR-16 downregulation through analysis of their methylation profile by methylation-specific PCR on DNA isolated from MEF TPM3-ALK-positive cells before (ALK þ ) and after (ALKÀ) ALK inactivation by doxycycline. As shown in Figure 3a , the miR-16-1 putative promoter was found non-methylated in both ALK þ and ALKÀ cells. Our data show that miR-16 downregulation is not mediated by an epigenetic mechanism.
ALK oncogene tyrosine kinase activity and hypoxia marker HIF1a may be involved in miR-16 downregulation in MEF TPM3-ALK cells
We next analysed whether regulation of miR-16 and VEGF was dependent upon functional ALK activity. First, we confirmed that TPM3-ALK kinase activity was inhibited following treatment with the ALK tyrosine kinase inhibitor, crizotinib, 30 by using ) were performed to detect changes in VEGF expression levels 48 h after transfection. First, miR-16 was normalized to SnoRNA202 and VEGF mRNA to S14 rRNA then both were normalized to Sc experiments (b, c). Bars represent SD and asterisks depict statistically significant differences compared with scramble (*Po0.05, **Po0.01, ***Po0.001; Student's t-test). Each experiment was performed in triplicate and repeated three times. RT-qPCR assays were performed to determine VEGF expression at the protein and mRNA level. (c) Endogeneous miR-15a and miR-16 levels were evaluated by RT-qPCR. miR-16 and miR-15a were normalized to Sno202 and VEGF mRNA to S14 rRNA. Bars represent standard deviation and asterisks depict statistically significant differences (*Po0.05; Student's t-test). Doxycycline was added or not to repress (ALKÀ) or induce (ALK þ ) TPM3-ALK expression. Each experiment was performed in triplicate and repeated three times.
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western-blotting to confirm loss of TPM3-ALK autophosphorylation (Figure 3b and Supplementary Data). Using RT-qPCR we also observed that, in cells treated with crizotinib, miR-16 levels were decreased, although not significantly, following ALK tyrosine kinase inhibition (Figure 3c ). This result suggests that ALK tyrosine kinase activity may partially contribute to underexpression of miR-16.
As hypoxia and HIF1a are known regulators of miR-16 expression, we analysed the expression profile of HIF1a in ALK þ and ALKÀ MEF cells. ALK inactivation via crizotinib resulted in significantly lower HIF1a expression (Figure 3d ) when compared with ALK-expressing cells (ALK þ ). Together, these results suggest that the expression of ALK and HIF1a is a prerequisite for miR-16 downregulation in ALK-positive cells.
In vivo repression of onco-ALK tumor growth and angiogenesis by miR-16 over-expression 
Association between miR-16 expression and VEGF levels in human ALK-positive lymphomas
To investigate a possible association between miR-16 expression and VEGF levels in human ALK þ cells, we looked at whether miR-16 was downregulated in ALCL tumor samples using RT-qPCR. We observed miR-16 levels to be significantly lower in ALK-positive ALCL lymph node biopsies (n ¼ 20) when compared with ALK-negative ALCL biopsies (n ¼ 6) (P: 0.0068) (Figure 5a ). We then sought to identify the mechanisms involved in the reduction of miR-16 mRNA in ALK-expressing cells by searching for DNA structural or epigenetic modifications. As observed in the mouse models, the miR-16 downregulation in ALCL patients was not related to DNA promoter epigenetic methylation (Supplementary Figure S3) or DNA deletion; in the 32 ALK þ ALCL cases tested, comparative genomic hybridization array analysis (Supplementary Data) shows and only one case with a deletion of the 13q14.2 region coding for miR-16-1 and no deletion of the miR-16-2 region coding, 3q25.33 (data not shown).
Next, we wanted to investigate VEGF mRNA and protein expression in ALK þ human cells. VEGF mRNA amounts were evaluated by RT-qPCR on lymph node biopsies from ALCL patients. Our results show that levels of VEGF mRNA were increased in ALK þ ALCL lymph node biopsies (n ¼ 20), when compared with ALKÀ ALCL biopsies (n ¼ 6) or reactive lymph miR-16 and VEGF expression in ALK lymphomas E Dejean et al nodes (n ¼ 5) (Figure 5b) . VEGF protein expression was tested using ELISA assays on ALCL sera and immunohistochemistry staining on tissue microarrays from lymph node biopsies of ALCL patients. We observed that VEGF protein expression was significantly enhanced in sera from ALK þ ALCL patients (n ¼ 17, p: 0.0242) when compared with sera from healthy donors (n ¼ 5) (Figure 5c ). Immunohistochemistry staining was performed on 86 ALK þ ALCL samples and 14 ALKÀ ALCL samples. Endothelial cells, myofibroblasts and rare reactive lymphocytes admixed with lymphoma cells were used as an internal positive control and, as expected, were positive for VEGF (data not shown). In the tumor cells, we found no significant variation in VEGF expression between ALK þ and ALK-samples. Indeed, VEGF staining was detected in 68% (59 of 86) of ALK þ patients and in 57% of ALKÀ patients (8 of 14). However, a low VEGF staining intensity was predominantly seen in ALKÀ ALCL, while variations in the intensity of the staining was observed in ALK þ ALCL samples; some ALK þ ALCL showed strong VEGF staining, whereas other showed a moderate to weak staining, as illustrated for 8 cases in Figure 6a . Importantly, we also observed HIF1a protein expression in ALK þ ALCL lymph nodes biopsies (Supplementary Figure S4) . Together, these results suggest that the ALK oncogene is able to induce VEGF expression, probably through both transcriptional and translational regulation, and involving both transcription factor HIF1-a and miR-16. Finally, we used RT-qPCR to search for a correlation between VEGF protein levels, as assessed by immunohistochemistry, and the amount of endogeneous miR-16 in ALK þ ALCL cells. The percentage of tumoral cells expressing VEGF was graded as follows: 0: negative (0%); 1: o50%; 2: 50-75% and 3: 475%. We noted a strong inverse correlation between the amount of miR-16 and the VEGF grade of ALK þ tumoral cells (Pearson's correlation test, R 2 ¼ 0.9768, Figure 6b ). In the majority of the cases, low and intermediate miR-16 expression (relative amount o2) was associated with more than 50% of tumoral cells (c) VEGF expression was measured using an ELISA assay on sera (c) from ALK þ and ALKÀ ALCL. VEGF mRNA amounts were normalized to reactive lymph nodes. Bars represent SD and asterisks depict statistically significant differences (*Po0.05 and **Po0.01; Student's t-test). Each experiment was performed in triplicate. The number of biopsies in each group is denoted by the n value.
miR-16 and VEGF expression in ALK lymphomas E Dejean et al expressing VEGF (Figure 6b ). In contrast, enhanced miR-16 expression was associated with a low percentage or no ALK þ tumoral cells expressing VEGF (Figure 6b ). Collectively, these results suggest that a decrease in miR-16 may be associated with an increase in VEGF protein levels in a substantial proportion of human ALK þ ALCL.
Discussion
Various hematological disorders and epithelial malignancies such as non-small cell lung cancer are associated with translocation of the ALK gene, located on chromosome 2p23. Around 17 chimera proteins have been characterized so far. 15, 16, 18, 19, 31 The majority of ALK translocations lead to diffuse large B-cell lymphomas and ALCL, a peripheral T-cellderived malignancy. NPM-ALK and TPM3-ALK are the main translocations recorded in ALCL. 32 A direct role for NPM-ALK in cellular transformation has been shown both in vitro and in vivo, and such studies have shed light on the mechanisms of malignant transformation by this oncoprotein. 33, 34 These mechanisms include activation of several downstream signal-transduction pathways, which regulate cell survival, proliferation, migration and, more recently, hypoxia. 20, 24 Although hypoxia has been reported to upregulate HIF-1a and VEGF in ALK-positive (ALK þ ) ALCL, 20 so far no studies have implicated it in angiogenesis in ALK tumor development.
In this study, we have used onco-ALK (NPM-ALK and TPM3-ALK) cellular and mouse models conditional for ALK expression 25, 26 to report for the first time, an increase in VEGF secretion both in vitro and in vivo. The increase in VEGF secretion in these models was not seen in normal cells, that is, following doxycycline-induced onco-ALK inactivation. Importantly, high VEGF serum levels were also detected in ALK þ ALCL patients when compared with healthy donors. These results led us to search for the underlying mechanism for this VEGF upregulation following ALK expression.
Extensive literature has shown that VEGF levels are tightly regulated at transcriptional, post-transcriptional and translational levels. 5, 6 Recently, miR-16 was shown to regulate VEGF mRNA stability and protein expression levels. 14, 29 In this study we have demonstrated that miR-16 is downregulated upon ALK expression both in vitro and in vivo using our onco-ALK conditional cellular and mouse models for ALK tumorigenesis. 25, 26 Importantly, a weaker expression of miR-16 was also observed in ALK þ ALCL patients when compared with ALKÀ ALCL patients.
The mechanisms for regulation of miRNA levels are not yet understood, despite the wealth of publications about the biological effects of miRNAs. A few reports have shown that downregulation of some miRNAs in haematopoietic cancer occurs through epigenetic factors or by genomic abnormalities. This has been observed for the miR-16 sequence at chromosomal locus 13q14, which is deleted in more than 50% of chronic lymphocytic leukemia or multiple myeloma patients. 9 ,10 ALK þ ALCL harbor genomic alterations including 13q losses but the locus 13q14 is rarely lost. 35, 36 In accordance with these data, we did not observe any abnormalities on chromosome 13 in ALK lymphomas from onco-ALK conditional transgenic mouse models and in only one of the human ALK þ ALCL samples. We also found that miR-16 downregulation was not related to DNA promoter epigenetic methylation changes in both the onco-ALK mouse models and in the human ALK þ ALCL samples. As we found an over-expression of HIF1a in ALK þ tumoral cells, we cannot rule out a possible hypoxia-mediated mechanism for miR-16 downregulation, as previously described by Hua et al. miR-16 and VEGF expression in ALK lymphomas E Dejean et al expression of miR-16 leads to a reduction in tumor growth, microvessel density and serum VEGF levels in MEF TPM3-ALK cells engrafted into nude mice. In human ALK þ tumors, we were able to demonstrate for the first time a strong inverse correlation between miR-16 and VEGF expression levels. Nevertheless, as the increase in VEGF mRNA was detected in ALK þ lymphoma cells, that is, in conditional transgenic models as well as ALCL patients, we suggest that VEGF is regulated at both transcriptional, as reported by Marzec et al., 20 and posttranscriptional levels in ALK þ ALCL.
Several trials have been opened for ALK þ tumors (http:// www.ClinicalTrials.gov). Only one agent, PF-02341066/crizo tinib, an inhibitor of the tyrosine kinase activity of both ALK and the MET oncogene, 30 has recently reached the clinical arena in the treatment of ALK þ non-small cell lung cancer. 37 Relapsed advanced ALK þ ALCL are also sensitive to ALK inhibition by crizotinib. 38 However, recently two secondary mutations were reported following ALK inhibitor treatment. 39 They were within the kinase domain of the EML4-ALK oncogene involved in nonsmall cell lung cancer, and conferred marked resistance to crizotinib. 39 As ALK signaling activates multiple downstream pathways, it is reasonable to speculate that small molecules, targeting key effectors within these pathways, will represent valuable targets to kill ALK þ cancer cells. Therefore, the development of combined therapies should help prevent the occurrence of resistance. 40 To this end, we recently demonstrated the efficiency of an antibody against CD160 in TPM3-ALK-induced fibroblast tumors in athymic nude mice. 41 This unusual antiangiogenic therapeutic is a glycophosphatidylinositol-anchored protein which is expressed by growing but not quiescent endothelial cells. 42 We found that the antibody not only inhibited tumor vascular density but also slowed down the growth of ALK tumors. 41 Anti-angiogenic strategies have become an important therapy for solid tumors 43 as well as hemato-lymphoid malignancies. 44 Importantly, an improvement in response, progression-free survival and/or overall survival has been demonstrated when conventional therapy was supplemented by VEGF inhibitors. As miRNAs can act both as oncogenes and tumor-suppressor genes, a very appealing therapeutic option is the combination of miRNAs with chemotherapy. 45 Indeed, several studies in vitro and in vivo using anti-miRNA molecules (antagomirs), LNAanti-miRNA oligonucleotides or anti-miRNA oligonucleotides, have validated the efficiency of such agents in both solid tumors 46 and haematopoietic malignancies. 47 Importantly, the first clinical trial applying anti-miRNA agents as drugs has already been launched. 48, 49 In conclusion, our results report a new fundamental process for ALK-mediated tumorigenesis involving angiogenesis and VEGF upregulation through, at least in part, miR-16 downregulation. These new data should encourage further work to optimize multi-target therapies and increase the chances of eradicating ALK þ tumors.
